Alumis (ALMS) Reiterated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Alumis Inc (NASDAQ: ALMS).

The analyst commented, "Our derms, working in academic centers, are biologics people and not the key prescriber base for next-gen orals. They expect oral IL-23 Icotyde (JNJ, NC) to find a market, but think orals in psoriasis face a higher bar than in AD given existing every-12-week biologic options. TB testing is viewed as a barrier to uptake for Sotyktu, so our derms will be looking to see if this will be a requirement for the next-gen TYK2i's from ALMS (OW, ES) and TAK (NC)."

For an analyst ratings summary and ratings history on Alumis Inc click here. For more ratings news on Alumis Inc click here.

Shares of Alumis Inc closed at $8.40 yesterday.

You May Also Be Interested In

• Texas Capital Securities Starts Porch Group Inc. (PRCH) at Buy
• Wedbush Downgrades Compass Therapeutics (CMPX) to Neutral
• KB Home (KBH) Tops Q3 EPS by 16c